Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
47
GYRE Quote, Financials, Valuation and Earnings
Last price:
$6.81
Seasonality move
:
12.42%
Day range:
$6.90 - $7.06
52-week range:
$6.11 - $13.75
Dividend yield:
0%
P/E ratio:
185.79x
P/S ratio:
6.49x
P/B ratio:
6.67x
Volume:
61.9K
Avg. volume:
77.7K
1-year change:
-41.65%
Market cap:
$680.1M
Revenue:
$105.8M
EPS (TTM):
$0.04
Analysts' Opinion
-
Consensus RatingGyre Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $18.00, Gyre Therapeutics, Inc. has an estimated upside of 154.96% from its current price of $7.06.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $7.06.
Fair Value
-
According to the consensus of 2 analysts, Gyre Therapeutics, Inc. has 154.96% upside to fair value with a price target of $18.00 per share.
GYRE vs. S&P 500
-
Over the past 5 trading days, Gyre Therapeutics, Inc. has underperformed the S&P 500 by -0.46% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Gyre Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Gyre Therapeutics, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Gyre Therapeutics, Inc. reported revenues of $30.6M.
Earnings Growth
-
Gyre Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Gyre Therapeutics, Inc. reported earnings per share of $0.03.
Enterprise value:
656.7M
EV / Invested capital:
--
Price / LTM sales:
6.49x
EV / EBIT:
54.57x
EV / Revenue:
6.12x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1,300.44x
Price / Operating cash flow:
528.63x
Enterprise value / EBITDA:
45.83x
Gross Profit (TTM):
$102.4M
Return On Assets:
8.53%
Net Income Margin (TTM):
11.02%
Return On Equity:
10.4%
Return On Invested Capital:
10.26%
Operating Margin:
22.66%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $86.3M | $191.3M | $107.3M | $25.5M | $30.6M | |
| Gross Profit | $82.9M | $184M | $102.4M | $24.5M | $28.9M | |
| Operating Income | $19.6M | $44.7M | $12M | $4.2M | $6.9M | |
| EBITDA | $20.4M | $46.9M | $14.3M | $4.7M | $7.6M | |
| Diluted EPS | -$8.01 | -$0.95 | $0.04 | $0.01 | $0.03 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $74M | $30.2M | $5.1M | $54.8M | $98.6M | |
| Total Assets | $78.5M | $31M | $10M | $125.2M | $159.4M | |
| Current Liabilities | $17.3M | $1.6M | $1.8M | $14.7M | $15.9M | |
| Total Liabilities | $17.8M | $1.6M | $6.4M | $26.8M | $22M | |
| Total Equity | $60.7M | $29.4M | $3.5M | $98.5M | $137.4M | |
| Total Debt | $550K | -- | -- | $1.1M | $539K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $64.8M | $36.7M | $2M | $1.7M | $5M | |
| Cash From Investing | -$90.3M | -$42.8M | -$4.3M | -$2.4M | -$1.2M | |
| Cash From Financing | $45M | $16.5M | $26.9M | $374K | $50K | |
| Free Cash Flow | $56.1M | $25.8M | -$505K | $980K | $4.3M | |
GYRE
Sector
Market Cap
$680.1M
$28.1M
Price % of 52-Week High
51.35%
50%
Dividend Yield
0%
0%
Shareholder Yield
-3.94%
-1.54%
1-Year Price Total Return
-41.65%
-17.67%
Beta (5-Year)
2.906
0.503
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$7.15
200-day SMA
Sell
Level
$8.07
Bollinger Bands (100)
Sell
Level
7.33 - 8.11
Chaikin Money Flow
Sell
Level
-305.2K
20-day SMA
Sell
Level
$7.54
Relative Strength Index (RSI14)
Sell
Level
38.17
ADX Line
Sell
Level
14.37
Williams %R
Buy
Level
-89.1892
50-day SMA
Sell
Level
$7.68
MACD (12, 26)
Sell
Level
-0.19
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
49.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (24.0872)
Buy
CA Score
(Annual)
Level (0.3129)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-5.7433)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, GYRE has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GYRE average analyst price target in the past 3 months is $18.00.
-
Where Will Gyre Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Gyre Therapeutics, Inc. share price will rise to $18.00 per share over the next 12 months.
-
What Do Analysts Say About Gyre Therapeutics, Inc.?
Analysts are divided on their view about Gyre Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Gyre Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Gyre Therapeutics, Inc.'s Price Target?
The price target for Gyre Therapeutics, Inc. over the next 1-year time period is forecast to be $18.00 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GYRE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Gyre Therapeutics, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GYRE?
You can purchase shares of Gyre Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Gyre Therapeutics, Inc. shares.
-
What Is The Gyre Therapeutics, Inc. Share Price Today?
Gyre Therapeutics, Inc. was last trading at $6.81 per share. This represents the most recent stock quote for Gyre Therapeutics, Inc.. Yesterday, Gyre Therapeutics, Inc. closed at $7.06 per share.
-
How To Buy Gyre Therapeutics, Inc. Stock Online?
In order to purchase Gyre Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get GYRE Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GYRE
Sector
P/E ratio
185.79x
23.88x
PEG ratio
--
-0.01x
P/B ratio
6.67x
1.82x
Price / LTM sales
6.49x
1.59x
Growth Metrics
GYRE
Sector
Revenue growth
19.92%
4.73%
Earnings growth
166.41%
11.11%
Revenue (5-year growth)
--
6.46%
Earnings forecast
--
-$0.18
Profitability
GYRE
Sector
Profitability FY 2024
$101.9M
$3.6M
Return on invested capital
10.26%
-31.77%
Return on assets
8.53%
-28.18%
Return on equity
10.4%
-37.47%
Earnings Date
Last Earnings Date
Nov
7
Next Earnings Date
Mar
16
Estimated Next Earnings Date
Feb
6
Balance Sheet
GYRE
Sector
Total cash
$60M
$26.3M
Short term investments
$14.9M
$26M
Total assets
$125.4M
$76.9M
Long term debt
$539K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
45
CTEV alert for Jan 2
Claritev Corp. [CTEV] is down 20.7% over the past day.
Sell
47
ASTS alert for Jan 2
AST Spacemobile, Inc. [ASTS] is up 14.94% over the past day.
Sell
45
BIDU alert for Jan 2
Baidu, Inc. [BIDU] is up 15.01% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
